Suppr超能文献

ALK阳性弥漫性大B细胞淋巴瘤

ALK-positive diffuse large B-cell lymphoma.

作者信息

Bubała Halina, Małdyk Jadwiga, Włodarska Iwona, Sońta-Jakimczyk Danuta, Szczepański Tomasz

机构信息

Department of Pediatric Hematology and Oncology, Silesian Medical Academy, Zabrze, Poland.

出版信息

Pediatr Blood Cancer. 2006 May 1;46(5):649-53. doi: 10.1002/pbc.20396.

Abstract

Anaplastic lymphoma kinase (ALK) positive diffuse large B-cell lymphoma (DLBCL) is a rare subtype of non-Hodgkins lymphoma. Five such cases have been described in children. We present a 9-year-old boy, in whom diagnosis of DLBCL has been established in addition to congenital multiple enchondromatosis. Immunohistopathological evaluation of tumor biopsy established the final diagnosis of ALK + DLBCL. The clathrin gene (CLTC)-ALK fusion underlying aberrant expression of ALK in the present case was demonstrated by interphase fluorescence in situ hybridization (FISH) using break-apart rearrangement probes for ALK and CLTC. The disease in this patient was highly resistant to applied chemotherapy regimens and to radiotherapy. Analysis of the disease course in our patient and review of other cases reported previously show that ALK + DLBCL can be an aggressive malignancy that can be cured with conventional chemotherapy protocols only at stage of localized disease.

摘要

间变性淋巴瘤激酶(ALK)阳性弥漫性大B细胞淋巴瘤(DLBCL)是一种罕见的非霍奇金淋巴瘤亚型。儿童中已描述了5例此类病例。我们报告一名9岁男孩,除先天性多发性内生软骨瘤外,还确诊为DLBCL。肿瘤活检的免疫组织病理学评估确立了ALK + DLBCL的最终诊断。通过使用针对ALK和CLTC的断裂重排探针进行间期荧光原位杂交(FISH),证实了本例中ALK异常表达背后的网格蛋白基因(CLTC)-ALK融合。该患者的疾病对应用的化疗方案和放疗高度耐药。对我们患者病程的分析以及对先前报道的其他病例的回顾表明,ALK + DLBCL可能是一种侵袭性恶性肿瘤,仅在局限性疾病阶段可通过传统化疗方案治愈。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验